Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 39Unknown 7Terminated 7Withdrawn 5Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pediatric Solid Tumor, Unspecified, Protocol Specific 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ondansetron × Clear all
NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Sun Yat-sen University

Phase 3 Recruiting
376 enrolled
Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡